Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Sarepta Therapeutics
AddedFeb 15, 2024
UpdatedJul 3, 2026
Sarepta Therapeutics

Sarepta Therapeutics

Public

Sarepta Therapeutics, a US-based biopharmaceutical firm, specializes in medical research and drug development.

HQ
Cambridge, MA, US
Founded
1980
Overview
Compare
Fundraising
Employees
Website

Sarepta Therapeutics, founded in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for treating rare diseases. The company's core mission is to develop innovative treatments for patients with severe and life-threatening genetic disorders. Sarepta's product portfolio includes EXONDYS 51 and VYONDYS 53, which are designed to treat Duchenne muscular dystrophy (DMD) in patients with specific genetic mutations.

Notable figures associated with Sarepta include gene therapy pioneer Jerry R. Mendell, M.D., who was named to the inaugural TIME100 Health list of the most influential people in global health. The company has achieved significant milestones, including the successful commercialization of its DMD treatments and ongoing advancements in gene therapy research. Sarepta's impact is profound, offering hope and potential life-changing treatments to patients with rare genetic diseases, while also promoting diversity and inclusion within its organizational culture.

Sarepta Therapeutics - Products & Services

  • Elevidys logo

    Elevidys

    Adeno-associated virus gene therapy delivering shortened micro-dystrophin for Duchenne muscular dystrophy.

    Competing Products

    SonoThera logo

Sarepta Therapeutics - Similar Companies

SonoThera logo

SonoThera

sonothera.com

Solid Biosciences logo

Solid Biosciences

solidbio.com

PTC Therapeutics logo

PTC Therapeutics

ptcbio.com

Editas Medicine logo

Editas Medicine

Triplet Therapeutics logo

Triplet Therapeutics

triplettx.com

DMD Therapeutics logo

DMD Therapeutics

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

ionispharma.com

Regeneron Ph logo

Regeneron Ph

regeneron.com

Taysha Gene Therapies logo

Taysha Gene Therapies

tayshagtx.com

bluebird bio logo

bluebird bio

bluebirdbio.com

Myosana Therapeutics logo

Myosana Therapeutics

Astria Therapeutics logo

Astria Therapeutics

astriatx.com

Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical

ultragenyx.com

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

amylyx.com

Amicus Therapeutics logo

Amicus Therapeutics

amicusrx.com

Sarepta Therapeutics - Quick Facts

Who are Sarepta Therapeutics' competitors?

Companies similar to Sarepta Therapeutics include SonoThera, Solid Biosciences, PTC Therapeutics and Editas Medicine.

When was Sarepta Therapeutics founded?

Sarepta Therapeutics was founded in 1980.

Where is Sarepta Therapeutics' headquarters located?

Sarepta Therapeutics' headquarters is located in Cambridge, MA, US.

When was Sarepta Therapeutics' last funding round?

Sarepta Therapeutics' most recent funding round was for $6M (USD) in September 2022.

How much has Sarepta Therapeutics raised to-date?

As of Sep 14, 2022, Sarepta Therapeutics has raised a total of $1.4B (USD).

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics has 1,162 employees as of Feb 6, 2024.

Sarepta Therapeutics - Classification

Ownership
  • Public
Technology
  • Biotech
  • Geneai
Geographic Exposure
  • United States
Revenue
  • Recurring
Tags
  • Biotech
Unique IDs
  • ein: 930797222
  • secCik: 0000873303
  • ticker: SRPT
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 541500Computer Systems Design and Related Services
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541510Computer Systems Design and Related Services
  • 325412Pharmaceutical Preparation Manufacturing
  • 541511Custom Computer Programming Services
SIC
  • 2800Chemicals And Allied Products
  • 7300Business Services
  • 2830Drugs
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 2834Pharmaceutical Preparations
  • 7371Computer Programming Services
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 19 more industry codes
NAICS
  • 513200Software Publishers
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541000Professional, Scientific, and Technical Services
  • 623000Nursing and Residential Care Facilities
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research